Sphingolipid Profiles Distinguish Lung Fibrosis Types

Researchers at CHEST 2026 reported blood and breath sphingolipid signatures that separate idiopathic pulmonary fibrosis from fibrotic hypersensitivity pneumonitis.

Updated on Nov. 2, 2026 in Asthma

Bold vector editorial illustration of two groupings of plain glass sample vials in a simple rack, one with amber liquid and one with clear, against a cream field. — Researchers at CHEST 2026 reported that blood and exhaled-breath sphingolipid profiles can distinguish idiopathic pulmonary fibrosis from fibrotic hypersensitivity pneumonitis without invasive testing. AI Illustration. Upload story photo >

Researchers presented sphingolipid profiling data at the CHEST 2026 Annual Meeting showing that plasma and exhaled breath condensate signatures differ between healthy adults, people with idiopathic pulmonary fibrosis, and those with fibrotic hypersensitivity pneumonitis. The findings were shared during an interstitial lung disease session.

Why it matters

Fibrotic interstitial lung diseases are difficult to tell apart, and distinguishing them typically depends on multidisciplinary review. A noninvasive biomarker approach could support earlier and more precise classification of these conditions.

Targeted mass spectrometry of plasma and exhaled breath condensate from 101 participants (33 IPF, 40 fibrotic HP, 28 healthy controls) showed distinct sphingolipid patterns, with IPF hexosylceramide C18:1 correlating with DLCO (R2 = 0.40, P = .002). Whether these patterns hold in larger or independent cohorts remains unknown.

The players

CHEST

The American College of Chest Physicians is a professional medical society that hosts an annual meeting and publishes research and guidance in pulmonology and critical care.

Virginia Commonwealth University

VCU is a public research university in Richmond, Virginia, whose institutional review board approved the study.

The details

Researchers analyzed patients' plasma and exhaled breath condensate samples stored in an institutional biorepository, with diagnoses confirmed through multidisciplinary ILD conference review. Clinical measures including pulmonary function testing and GAP indices were drawn from electronic medical records. In plasma, dihydrosphingosine and ceramide C24:0 differed between IPF and fibrotic HP, while exhaled breath condensate markers distinguished the two conditions and plasma markers tracked GAP scores.

October 12, 2026: CHEST issued a news release on the sphingolipid profiling research.
October 19, 2026: The findings were presented during the ILD: Clinical Roundup session.
October 18-21, 2026: The CHEST 2026 Annual Meeting was held in Phoenix, Arizona.

Health Landscape

The work extends the ILD research track at the annual CHEST meeting by seeking blood and breath biomarkers that could reduce reliance on invasive sampling for distinguishing fibrotic conditions. It builds on a diagnostic challenge that has long required specialist multidisciplinary review to resolve.

If the biomarker approach is validated, patients with fibrotic lung disease could eventually have a noninvasive blood or breath test added to their diagnostic workup. For now, diagnosis continues to rely on established clinical and multidisciplinary review.

The takeaway

Noninvasive biomarkers may eventually help clinicians separate similar-looking fibrotic lung diseases sooner. Patients should continue to rely on their specialists for diagnosis until such tests are validated.